Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Gross Margin (2022 - 2026)

Indivior Pharmaceuticals has reported Gross Margin over the past 5 years, most recently at 87.38% for Q1 2026.

  • For Q1 2026, Gross Margin rose 430.0% year-over-year to 87.38%; the TTM value through Mar 2026 reached 81.25%, up 177.0%, while the annual FY2025 figure was 80.23%, 33.0% down from the prior year.
  • Gross Margin for Q1 2026 was 87.38% at Indivior Pharmaceuticals, up from 81.56% in the prior quarter.
  • Over five years, Gross Margin peaked at 87.38% in Q1 2026 and troughed at 73.25% in Q3 2025.
  • A 5-year average of 81.84% and a median of 82.77% in 2022 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: tumbled -831bps in 2024 and later surged 920bps in 2025.
  • Year by year, Gross Margin stood at 82.16% in 2022, then grew by 0bps to 82.25% in 2023, then grew by 1bps to 83.22% in 2024, then decreased by -2bps to 81.56% in 2025, then grew by 7bps to 87.38% in 2026.
  • Business Quant data shows Gross Margin for INDV at 87.38% in Q1 2026, 81.56% in Q4 2025, and 73.25% in Q3 2025.